MDL | MFCD00923611 |
---|---|
Molecular Weight | 381.35 |
Molecular Formula | C18H18F3N3O3 |
SMILES | FC(C1=NC(C2=CC(C)=C(OCCCC3=CC(C)=NO3)C(C)=C2)=NO1)(F)F |
Pleconaril is a capsid inhibitor used previously to treat enterovirus infections. Pleconaril is effective in inhibiting replication with an IC50 of 50 nM. Target: enterovirus Pleconaril is a capsid inhibitor designed to dock within a hydrophobic pocket formed by the capsid proteins VP1, VP3 and VP2. Pleconaril leads to stiffening of the capsid structure, preventing RNA release into the cell. Pleconaril has been used as treatment on a compassionateuse basis in neonates and immunodeficient patients with severe EV infections.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00394914 | Merck Sharp & Dohme LLC |
Asthma|Common Cold|Picornavirus Infection|Rhinovirus
|
August 2006 | Phase 2 |
NCT00031512 | National Institute of Allergy and Infectious Diseases (NIAID) |
Enteroviral Sepsis
|
June 2001 | Phase 2 |
NCT04838145 | Oslo University Hospital |
Type1 Diabetes Mellitus|Enterovirus
|
August 30, 2018 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 100 mg/mL ( 262.23 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.6223 mL | 13.1113 mL | 26.2226 mL |
5 mM | 0.5245 mL | 2.6223 mL | 5.2445 mL |
10 mM | 0.2622 mL | 1.3111 mL | 2.6223 mL |
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution